Monopar Therapeutics Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Note 4 - Capital Stock (Details Textual)

Note 4 - Capital Stock (Details Textual)				12 Months Ended
Note 4 - Capital Stock (Details Textual)	Sep. 24, 2025 USD ($) $ / shares shares	Aug. 12, 2024 shares	Aug. 05, 2024 shares	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Sep. 30, 2025	Sep. 23, 2025	Dec. 23, 2024 $ / shares shares	Jun. 30, 2024 shares	Mar. 31, 2022 shares	Apr. 30, 2020 shares	Oct. 31, 2017 shares	Apr. 30, 2016 shares
Common Stock, Shares Authorized (in shares)				40,000,000	40,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share) \| $ / shares				$ 0.001	$ 0.001
Common Stock, Shares, Outstanding (in shares)				6,692,140	6,102,560
Proceeds from Issuance of Common Stock \| $				$ 0	$ 4,202,245
Payments for Repurchase of Common Stock \| $				$ 34,999,957	$ (0)
Common Stock, Shares, Issued (in shares)				6,692,140	6,102,560
Share Purchase Agreement With Tactic Pharma [Member]
Payments for Repurchase of Common Stock \| $	$ 35,000,000
Stock Repurchased During Period, Shares (in shares)	550,229
Shares Acquired, Average Cost Per Share (in dollars per share) \| $ / shares	$ 63.6098
Tactic Pharma, LLC [Member] \| Monopar Therapeutics [Member]
Ownership Percentage							13.40%
Underwriting Agreement [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares								$ 23.79
Public Offering [Member]
Shares Issued, Price Per Share (in dollars per share) \| $ / shares	$ 67.67
Stock Issued During Period, Shares, New Issues (in shares)	1,034,433
Proceeds from Issuance or Sale of Equity \| $	$ 126,900,000
Proceeds from Issuance of Common Stock \| $	70,000,000
Proceeds from Issuance of Common Stock, Net \| $	65,800,000
Proceeds from (Repurchase of) Equity \| $	$ 91,900,000
Pre-funded Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)								882,761
Class of Pre-Warrant or Right, Price Per Share (in dollars per share) \| $ / shares								$ 23.789
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares								$ 0.001
Class of Pre-Warrant or Right, Number, Securities Purchase Agreement (in shares)								882,761
Class of Pre-Warrant or Right, Maximum Beneficial Ownership Percentage					9.99%			9.99%
Class of Warrant or Right, Maximum Beneficial Ownership Percentage						19.99%
Class of Warrant or Right, Outstanding (in shares)				1,843,303
Class of Warrant or Right, Issued (in shares)				960,542	882,761
Pre-funded Warrants [Member] \| Public Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	960,542
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) \| $ / shares	$ 0.001
Class of Warrant or Right, Price per Warrant (in dollars per share) \| $ / shares	$ 67.669
Proceeds from Issuance of Warrants \| $	$ 65,000,000
Proceeds from Issuance of Warrants, Net \| $	$ 61,100,000
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)		1,420,000	7,100,000						5,100,000	1,020,000	620,000	320,000	140,000
Common Stock, Shares, Outstanding (in shares)		3,520,427							17,601,827
Monopar Therapeutics Inc. 2016 Stock Incentive Plan [Member] \| Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio		5	5